Research programme: anticancer threpeutics - Genisphere

Drug Profile

Research programme: anticancer threpeutics - Genisphere

Alternative Names: FA-3DNA-siHuR; GL-231; GL-233; GL-238; GL-23X; GL-246; GL-2B2; GS-2A3

Latest Information Update: 14 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genisphere
  • Class Antineoplastics; Drug conjugates; RNA binding proteins; Small interfering RNA; Small molecules
  • Mechanism of Action DNA intercalators; RNA interference; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Ovarian cancer
  • Research Breast cancer; Glioblastoma; Pancreatic cancer

Most Recent Events

  • 09 Jun 2016 Research programme: anticancer threpeutics - Genisphere is available for licensing as of 09 Jun 2016.
  • 09 Jun 2016 Early research in Glioblastoma,Breast cancer and Pancreatic cancer in USA (unspecified route)
  • 09 Jun 2016 Preclinical trials in Ovarian cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top